NEW YORK, Jan. 23, 2017 /PRNewswire/ -- Prostate cancer has emerged as a disease with one of the highest incidences and mortality rates in males across the world. This situation has created a large unmet medical demand for better therapeutics by patients suffering from prostate cancer due to modest response generated by presently available therapeutics. Hormone based therapeutics and chemotherapeutics helped in improving the patient's condition but they have side effects and modest pharmacological benefits reflecting necessity for better product. Pharmaceutical companies focused their efforts to resolve this problem by increasing research and development activities by diverging more funds in this segment. As a result, prophylactic prostate cancer vaccine was developed and introduced in market which is going to witness competition from innovative products in next few years.
Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medicalcare. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years.
Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations.These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients.
Prostate cancer vaccines are prophylactic in nature due to which they can prevent the future incidences of cancer. Immune cells are primed to search and eliminate the cancerous cells due to which they are able to prevent relapse. Circulating cancerous cells are also targeted responsible for secondary cancer development is checked in the body. Efficacy of cancer vaccine could be monitored by checking PSA levels which may indicate improvement in patient's condition. However, these results may vary from patient to patient but significant improvement has been observed as compared to conventional therapeutic methods.Besides pharmacological benefits, this fact also reflects towards high marketing potential of prophylactic prostate cancer vaccine.
"Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" Report Highlights:
Introduction to Prostate Cancer Vaccine
Mechanism of Prostate Cancer Vaccines
Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase
Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines
Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines
Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation)
Read the full report: http://www.reportlinker.com/p04397352-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-prostate-cancer-vaccine-clinical-pipeline-insight-2015-300395106.html